Myocardial Injection With GSK-3β–Overexpressing Bone Marrow–Derived Mesenchymal Stem Cells Attenuates Cardiac Dysfunction After Myocardial Infarction
Rationale: Glycogen synthase kinase (GSK)-3β upregulates cardiac genes in bone marrow–derived mesenchymal stem cells (MSCs) in vitro. Ex vivo modification of signaling mechanisms in MSCs may improve the efficiency of cardiac cell-based therapy (CBT).
Objective: To test the effect of GSK-3β on the efficiency of CBT with MSCs after myocardial infarction (MI).
Methods and Results: MSCs overexpressing either GSK-3β (GSK-3β–MSCs), LacZ (LacZ-MSCs), or saline were injected into the heart after coronary ligation. A significant improvement in the mortality and left ventricular (LV) function was observed at 12 weeks in GSK-3β–MSC–injected mice compared with in LacZ-MSC– or saline-injected mice. MI size and LV remodeling were reduced in GSK-3β–MSC–injected mice compared with in LacZ-MSC– or saline-injected ones. GSK-3β increased survival and increased cardiomyocyte differentiation of MSCs, as evidenced by activation of an Nkx2.5-LacZ reporter and upregulation of troponin T. Injection of GSK-3β–MSCs induced Ki67-positive myocytes and c-Kit–positive cells, suggesting that GSK-3β–MSCs upregulate cardiac progenitor cells. GSK-3β–MSCs also increased capillary density and upregulated paracrine factors, including vascular endothelial growth factor A (Vegfa). Injection of GSK-3β–MSCs in which Vegfa had been knocked down abolished the increase in survival and capillary density. However, the decrease in MI size and LV remodeling and the improvement of LV function were still observed in MI mice injected with GSK-3β–MSCs without Vegfa.
Conclusions: GSK-3β significantly improves the efficiency of CBT with MSCs in the post-MI heart. GSK-3β not only increases survival of MSCs but also induces cardiomyocyte differentiation and angiogenesis through Vegfa-dependent and -independent mechanisms.
- mesenchymal stem cells
- glycogen synthase kinase-3β
- myocardial infarction
- cell-based therapy
- vascular endothelial growth factor A
- Received August 2, 2010.
- Revision received December 29, 2010.
- Accepted December 30, 2010.
- © 2011 American Heart Association, Inc.